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Human keratinocytes transport extracellular thymidine 
across the plasma membrane and incorporate it into DNA. 
Data presented here show that dipyridamole, a well-known 
inhibitor of facilitated diffusion of nucleosides, blocks the 
transport of thymidine i.nto human ke,rarinocyrcs in vitro. 
Dipyridamole (1.0 I'M) inhibited the transport of 3H-thy-
midine (0.2 I'M) into intracellular material by 75% and its 
subsequent salvage and incorporation into DNA by 48%. 
Dipyridamole (1 I'M) did not affect the growth of kerat-
inocytes in vitro bue did potentiate the growth inhibition 
caused by methotrexate (MTX) or 5-fluorouracil (5-FU). 
The growth of keratinocytes exposed to 0.1 I'M MTX for 8 d 
was inhibited by 32%. However, in combination with a non-
inhibitory concemration of dipyridamole (l ,uM), this con-
centration of MTX (0.01 I'M) inhibited the growth of ke-
T he normal epidermis is a continually renewing, strati-fied epithel ial tissue containing proliferating kerat-inocytes that are located primarily in the basal layer 11 - 3]. The proliferating keratinocytes synthesize DNA and, among other requirements. need a supply 
of the four dcoxynucleoside triphosphates, which are the subsrr:ucs 
for DNA polymerase 14 ,5]. Thymidine triphosphate (dTTP) is one 
of these essential precursors. The replicating kerarinocyte. like 
other proliferating mammalian cdls. can synthesize dITP by tWO 
possible routes (Fig 1) 14). The cell can synthesize dTMP from 
amino acids, CO2• and AT P via a 10-step route- denoted as the de 
novo pyrimidine pathway. dTMP can then be phosphorylated in 
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ratinocytes by 93%. Thymidine in culture medium reversed 
the cytotoxicity of MTX. However, in the presence of dipy-
ridamole. thymidine in the culture medium did not reverse 
the action of MTX. The synergistic interaction between 
MTX and dipyridamole was also observed with 5-FU and 
dipyridamole. 5-FU (0.5 I'M) inhibited cell growth by 30% 
but in combination with dipyridamole (1 I'M), inhibited cell 
growth by 86%. These data are consistent with the theory 
that inh ibiting thymidine salvage by blocking transpon of 
extracellular thymidine potentiates the growth inhibitory 
action of inhibitors of de novo pyrimidine biosynthesis in 
human keratinocytes. Combination chemotherapy, such as 
methotrexate plus dipyridamole, might be efficacious in the 
treatment of byperproliferative diseases of the epidermis. 
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two steps to dTTP. Alternatively, the cell can synthesize dTMP via 
the saJvage pathway in which thymidine, derived from extracellular 
sources, is phosphorylated by thym.idine kinase. There is ample 
ev idence that kerarinocytes are capable of bath de noyo and salvage 
synthesis of dITP [6-81. 
The sa lvage of thymidine commences with the uptake of extra-
cellular thymidine into the cell. In many cell rypes, e-xtraceUular 
thymidine is transported by a facilitated diffusion mechanism that 
can be blocked by nucleoside ttansport inhibitors [9] . Nucleoside 
transport inhibitors are a class of chemically diverse structures. and 
the- mechanisms by which they act have been well studied 19 - 12J. 
Nucleoside trampon inhibitors include dipyridamole, al so known 
as Persantin. dilaz.ep. and nitrobenzylth.ioinosine {9.1 0, 13]. Dipy-
ridamole and dilazep arc used clinically as vasodilators and inhibi-
tors of platelet aggregation, and the action of dipyridamole as a 
vasodilaror is now thought to be due to inhibition of nucleoside 
transport r14]. Although these transport inhibitors interfere with 
the salvage of nucleosides such as thymidine, they are not potent 
inhibitors of DNA synthesis presumably because cells utilize de 
novo pathways to make necessary nucleic ;:acid precursors. 
The use of dipyridamole to block the rransport and subsequent 
utilization of thymidine has been explored recently in a number of 
combination chemotherapeutic regimens to treat malignant neo-
plastic diseases. These combination chemotherapies have been de-
signed to simultaneously block both the salvage and de noyo path-
ways leading to the synthesis of dTTP by using a nucleoside 
transport inhibitor in combination with an inhibitor of de noyo 
pyrimidine biosynthesis [1 5J. One reason to expect a synergistic 
interaction is that the growth inhibitory activity of many inhibitors 
of the de noyo pyrimidine pathway is reduced by the presence of 
thymidine. which rescues cells by circumventing the blockade of 
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Figure 1. Biochemical Pathways of Thymidine Metabolism. Cel ls can syn-
thesize dTMP via the de novo pathway (domd orrow) or by the salvage 
pathway by wbich thymidine is transpond into the cell (dashed, two-way 
",row) and phosphorylated by thymidine: kinase (dashtd onto-way tlrroul). 
dTMP can be converted in twO sups to dITP. which is one of four deoxyn-
udeoside triphosph;.ter. needed for DNA synthesis. Abbreviations: dUMP, 
3' -de--oxyuridine S' -monophosphate; dR-I-P, deoxyribose-l-phosphate; 
dTMP, thymidine 5' -monophosphate; dITP, thymidine 5' -rriphosphate. 
the de nOVO pyrimidine pathway [16.17]. A number of such combi-
nations have been tested in viuo. Such studies show that nudeoside 
transport inhibitors, such as dipyridamole, can potentiate the 
growth inhibitOry action of inhibitors of de novo pyrimidine bio-
synthesis \15.18-21). 
The use of nucleoside transport inhibitors has relevance in vivo 
because the circulatio.n contains a low but sustained amount of thy-
midine available for. salvage. Indeed. thymidine in the circulation 
has been shown to. modulate the action of inhibitors such as metho-
trexate in vivo (16]' Recently. clinical trials were initiated to deter-
mine the efficacy of such combinations as MTX plus dipyridamole 
[22.23J and 5-FU plus dipyridamole [24J for treatment of neoplastic 
diseases. 
T he epidermis is subject to.a number of hyperplastic diseases thar 
are treated with inhibitors of DNA synthesis such as MTX and 
5-FU \25.28]. As ane step in a rational approach to combination 
chemotherapy for derm.atologic diseases. we undertook a study of 
dipyrida.mole co determine ifit acted as a nucleoside transport inhib-
itor in human keratinocytes and if dipyridamale would potentiate 
the cytofOxic activity of MTX and 5-FU in pro liferating keratino-
cytes in vitro. 
METHODS 
Primary Humao Keratinocytes Cell Cultures Primary cul-
tures of human neonatal foreskin kcratinocytes were grown on a 
feeder layer of irradiated 3T3 cells as previously described [3J. Pri-
mary cultures were maintained in complete medium consisting of 
Dulbecco's Modified Eagle's Medium suppleme.nted with 20% fetal 
bovine serum. hydrocortisone (0.4 p.g/ ml). epidennal growth fac-
tor (10 ng/ mI) , insulin (10 Jig/ ml). choleta toxin (100 pM) . peni-
cillin (100 U/ mI). and streptomycin (100 Jig/ mI). The Ca .... con-
centration was 1.8 mM. Preconf}uent, stratified cultures were 
washed with EDTA (0.2 gi L Hanks' balanced sah solution) to. re-
move fibroblasts and then with trypsin-EDT A (0.5 g trypsin and 
0.2 g EDT A / L in Hanks' balanced saJt solution) to remove kerat-
inocytes. 
Uptake of 3H .. Thymidioe into Keratinocytes Keratinocytes 
from a primary culture were suspended in DMEM at 4 X 106 cells/ 
mi. The keratinocytes were shaken in a water bath at 37° in medium 
with or without dipyridamole. After 20 min, 3H-thymidine 
(0.2.aM. 4 p.Ci/ ml) was added. Ten minutes after the addition of 
3H-thymidine. a 100,u1 sample of cell suspension was layered on 
top of a 400,ul microfuge tube containing 100,ul of oil (Paraffin: 
Silicon. 16: 84) on top of75 Jil of3N PCA. The tube was immedi-
ately centrifuged (13.000 rpm fot 1 min) and then frozen at -70' . 
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The middle oil layer separatc'i the upper layer. containing culture 
medium, from the: bottom layer. con.taining cells lysed by PCA [29]' 
The frozen tube was Cut through the oil partition and the upper and 
lower portions placed in separate scintillation vials and counted. 
Radioactiviry in the peA layer was taken as a measure of the intra-
cel lular uptake of thymidine. The nature of the intracellular metab-
alites of thymidine formed in 10 min was not determined. 
Incorporation of3H-Thymidine into DNA ofHumao Kerat-
inocytes In Vitro Secondary cultures of keralinocytes were pre-
pared in 35-mm dishes containing 3 feeder layer of irradiated 3T3 
cel ls. Well-strati6ed culrures were used 10 - 14 d after reaching 
confluence. C ultures of human keratinocytes were fed with 0.8 m1 
of DMEM alone or DMEM containing various concentrations of 
dipyridamole. After 1 h, 200,UI of3H-thymidine was added to give 
a final concentration of 0 .2,UM thymidine, 4,uCi/ml. After 2 h 
culture dishes were washt:d with PBS and then with cold 10% TCA 
to remave unincorporated radioactiviry. The cells were hydra lyzed 
with 3% peA at 90° for 30 min. The peA extract was transferred to 
a scintiUation vial. lncorporation of thymidine into DNA is taken to 
be rhe radioactivity in the TeA-insoluble PCA-hydrolyzable m.ate-
rial (30]. 
G rowth Studies For growth studies, secondary cultures ofkerat-
inocytes were prepared by plating 2 X 1 ()'I kerarinocyres into 
3s-mm dishes with complete MCDB-153. Complete MCDB- Is3 
is basal medium supplemented with epidermal growth factor {5 ngf 
mI}. insulin (5 Jig/ ml). hydrocortisone (0.4 Jlg/ ml) . ethanolamine 
(0.01 mM). phosphoethanolamine (0.01 mM), transferrin (10 Jig/ 
011 ) .. bov~e pi~ui~a~y extract (50 J.l.S pr.otein/~I). and additional 
anuno aCids lhlsndme (2.4 X lO-4M), Jso)eucme (7.5 X 1O-4M). 
methionine (9 X lO- SM). phenylalanine (9 X lO-SM). tryptophan 
(4.5 X lO-SM). and tyrosine (7.5 X lO-SM)]. The Co'" concentra-
tion is 0.1 mM. Basal MCDB-153 contains 3.uM thymidine. 
MCDB- t 53 without thymidine was formulated by Clonetics. Inc. 
(Boulder. CO). Cultures were fed with control and test media start-
ing the day after the cel ls were seeded. Cultures were fed every 2 co 
3 d with control and test media for 8 d. The cells in cultu,re djshes 
were enumerated. after trypsinization, in a Coul ter couuter or were 
stained with Rhodanile blue. 
Chetnicals DM£M and sterile tissue: culture solutions were pur-
chased from Gibco Laboratories (Grand Island, NY). Fetal bovine 
serum was purchased from JR Scientific (Woodland. CAl. Basal 
MCDB-153 w as obtained from Irvine Scientific (Santa Ana. CAl, 
and MCDB-153 without rhymidine was purchased from Clonerics. 
Inc. (Boulder, CO). 3H-Thymidine (20Cijmmole) was purchased 
from New England Nuclear (Boston, MA). Methatrexate. paren-
te ral (Lederle Parente.rals, Carolina, Pueno Rico), was reconstituted 
with sterile water and diluted in culture medjum for experimental 
use. Dipyridamole and 5-Auorouracil were purchased froIn Sigma 
Chemical Co. (Sf. Louis. MO); stock solutions were prepared in 
culture medium and sterilized by 6Jtration. Piritrexim was th.e gen-
G.5U UiQ 
DffOYItIOAMOLE IvMl 
Figure 2. Dipy ridamole Reduces Uptake of 3H-Thymidine into Human 
Kentinocyrcs. 3H-Thymidine (0.2,uM. 4 J,lCifml) w:a.s added to ::a suspen-
sion of kerncinocytes in the presence or absence of dipyrid2mole. After 10 
minI cells were separated from the extr2ccllular medium by centrifug2tion 
through a layer of oiL Cell -associated radioactivity was mC2SUred. The mean 
2nd range of data from a representative experiment are shown. 
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erous gi ft of Dr. Thomas Krenitsky (Burroughs Welcome Co., A 
Research Triangle Park. NC). 
RESULTS 
Effect of Dipyridamole on the Uptake of 3H~Thymidine 
into Keratinocytes The uptah of 3H-thymidine (0.2 J.LM. 
4 ,uCi/ml) into keratinocytes was rapid and reached a plateau within 
5 min (data not shown). After 10 min, intracellular thymidine was 
less than 5% of the ex tracellular thymidine, Dipyridamole (l ,uM) 
inhibited the uptake of3H-thymidine by more than 75% compared 
to comrol cells (Fig 2). The effect of dipyridamole on the uprah of 
3H-thymidine was dose dependent. 
Effect of Dipyridamole on the Incorporation of 3H~ Thymi. 
dine into DNA of Keratinocytes Confluent. stratified cultures 
of hum3n keratinocytes incorporated 3H-thymidinc (0.2,uM. 
4 JiCijml) iuro DNA (Fig 3). Dipyrid3mole inhibited incorpora-
tion of 3H-thymidine into DNA of kerarinocyres in a dose-depen-
dent fashion. A 50% inhibition of3 H-th ymidine incorporation into 
DNA was seen when cel ls were exposed to l,uM dipyridamole 
starting 1 h before [he thymidine pulse. 
Effect of Dipyridamole and Methotrexate on the Growth of 
Keratinocytes Cultures of keratinocytes grew fa 5.5 - 8 X lOS 
cells per dish in 8 d after seeding at 2 X 104 cells per dish and feeding 
with complete MCDB-153 (Fig 4). Dipyridamole at 1 pM in the 
medium did nor affect rhe growth of keratinocytes but 3 JIM dipy-
ridamole did inhibit cdl growth. The effect of MTX alone on the 
growth ofkeratinocytes was dose dependent: 0.05 ,uM MTX had no 
effecr on cel l growth. but 0.5 pM MTX inhibited cell growrh by 
approximately 70%. A non-inhibitory concentration of dipyrida-
mole (1 ,uM) increased the inhibitory effect of MTX subsrami2l1 y. 
MTX (0.01 I'M) inhibited cell growth by about 30%. but in the 
presence of 1 JiM dipyridamole. inhibited cell growth by over 90%. 
A O.OS,uM dose of MTX alone was non-inhibitory but inhibited 
cell growth by about 20% in the presence of 1 J1M dipyridamole. 
Effect of Thymidine on the Interaction of Dipyridamole 
with Methotrexate The previous growth cxpcrimems were con-
ducted in complete MCDB-153 formulated with 3 ,uM thymidine 
l3 1J. Thymidine is known to reverse the cytotoxic activiry of MTX 
in a number of cel l lines [16.17]' The influcnce of thymidine on the 
action of dipyridamole (1 ,uM). methotrexate (0.1 JiM). and a com-
bination of these agents was measured. The concentration of thymi-
dine (3 JiM) notmally found in MC DB-1S3 had no affect on kerat-
inocyte growth in the absence (Fig Sa) or in the presence (Fig 5b) of 
dipyridamole (1 ,uM). However. this same concentration of thymi-
dine nearly reversed the growth inhibition caused by O. t p M MTX 
(Fig 5c). The rescue- of cells by thymidine from the inhibitory action 
of MTX was nullified by 1 I'M dipyridamole (Fig Sd). 
Effect of Dip yridam ole and 5-Fluorouracil on the Growth of 
Keratinocytes The growth of keratinocytes was inhibited by 
about 30% when cells were grown in the presence of 0.5 ,uM 5-FU 
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Figure 3. Dipyridamole Reduces Incorporation of 3H.Thymidine infO 
DNA ofKerarinocytes. After:l 1-h pre-exposure of cultures todipyridOlmole. 
3H-thymidine (0.2 .uM. 4 JlCiJml) was added for 2 h. The udioactivity in 
the T e A-insoluble. PCA-hydrolyuble fraction w:u me:uured. The mean 
:lnd range of data from :l representative experiment .ue shown. 
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Fi.gure • . Dipyridamol(, and Methotrexate Synergisticall y Inhibit the 
Growth of Human Keratinocytes iJl vitro. Cu ltures of keratinocytes were 
fed th e day after sl':eding with medium comaining dipyridamole. methotrex-
;lte. or dipyridamoll': plus methorrexatc: control cultures were fed medium 
contain ing no drugs. Cu ltures were fed every 2 to 3 d with control or test 
medium for 8 d. Th t' num~r of cells per dish was determined using a 
Coulter Coulter (A) . The mean and range of data from a repre~ntative 
experiment is shown. Represenutive cultures were stained with Rhonclanile 
bluc (B). Culture dis hes showt'd a diffuse staining rypio.l of prc-confluen r 
cultures grow n in complt"tc MCna containing 0.1 mM Ca++. Abbrevia-
tions: MTX, mClhotrexate; DP, dipyridamole 
(Fig 6). ln the presence of l/tM dipyridamole, O.SI'M S-FU inhib-
ired cell growth by almost 85%. The effect of 1 ,uM S~FU also was 
enhanced by 1 liM dipyridamole. 
DISCUSSION 
Human keratinocytes salvage and uti lize extracellular thymidine. 
The first step in this proce-ss is the uptake of thymidine into the cell. 
Many, but nor all. mammalian ce lls transport nucleosidcs by facili-
rated diffusion. which is media ted by a high affinity membrane 
carri er with broad specificity for nucle-osides [9 - t 1.29]. Dipyrida-
mole is an inhibitor of the facilitated diffusion of nucleosides 
[10, 12.15J. O ur demonstration that dipyridamole inhibits the up-
cake- of extracellular thymidine into ke.ratinocyres suggests that fa-
cilitat.ed diffusion is [he major means by which keratinocyres trans-
port thymidine . 
Dipyridamole inhibits the transport of thymidine into kentino-
cyees and thereby prevents [he keratinocyte from utilizing an extra-
cellular source of thymidine [0 synthes ize thymidine nucleotides 
and DNA. Dipyridamole (1 ,uM) did not inhibit [he proliferation of 
keratinocytes exposed to the drug for 8 d. although this concentra-
tion of dipyridamole would be expected to give a significant. but not 
complete , inhibition of thymidine transport. These obse rvations 
with dipyridamole suggest that proliferation of keratinocytes in 
vitro may nor depend on the availability of thymidine in the culrure 
medium. In addition. keratinocytes grew as well in the culNre me· 
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Figure 5. Thymidine R~Ve[Se5 Growth Inhibition by Methotrexate. but 
not in the Presence of Di.pyridamole. Cultures of Ir.eutinocytes were fed the 
day after seeding with medium containing dipyrid:unole (1 JLM). metho-
trexate (0. t ,LIM), of dipyridamole plus methotrexate in medium without 
tnymidine: or with 3 JLM thymidi.ne. Controlcuh,ures wone fed medium with 
or withom thymidine-containing no drugs. Cultures were fed every 2 to 3 d 
with control or resl medium for 8 d. The number of cells per dish was 
dete rmined usi.ng a Coulter Counter . The mean and range of data &om a 
rcpresentati ... e experiment ;ICC shown. 
dium withour thymidine as in medium cOJltaining thymidine. 
Thus, rapid ly growing kerarinocytes must make use of de novo 
pathways to synthesize sufficient thymidine nucleotides co sustain 
growth. 
Dipyrid3.mole at a concentr3.tion of 3 pM moderately inhibited 
keratinocyte replication. In other in vitro systems, dipyricbrnole 
inhibited cell growtb at concentrations that were 3 to 10 times 
greater than the concentration producing signi6.cant inhibition of 
thymidine uptake [15,21 J. These high concentrations of dipyrida-
mole may inhibit growtb by producing an imbalance in the concen-
trations of all intracellular nucleorides as a result of the inhibition on 
transport of nucleosides both into and out of the cell. 
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Figure 6. Dipyridamol~ and 5-Fluorouracil Synergistic.;r.lIy Inhibit the 
Growth of Hum.;r,n Keradnocytes in vitro. Cultures of keratinocytes were 
fed the c:by after seeding with medium containing dipyridamole, 5-8uoro-
uracil , or dipyridamole plus 5-8uorouracil; control cultures were fed me-
dium containing no drugs. Cultures were fed every 2 to 3 d with comral or 
test medium for 8 & The number of cells per dish was determined using ::I 
Coulter Counter. The mean and range of data from a represenrative experi-
ment are shown. 
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Methotrexate inhibits the growth of rapidly prol iferating human 
keratinocytes in vitro and in vivo by inhibiting de novo pyrimidine 
biosynthesis [26,28.32]' It could be predicted that this action of 
MTX might be circumvented by providing an alternative source of 
pyrimidines. We have shown that in vitro. MTX was most effective 
in the absence of thymidine, and its action was reversed by the 
addltion of thymidine. Similarly. Flaxman et aJ demonstrated that 
kera tinocytcs treated with a growth-inhibitory concentration of 
MTX paradoxical ly incorporated a grc:ater amount of 3H-thymi-
dine than did control cdls 132). Presumably, cells treated with MTX 
rapidly salvage thymidine to overcome the depletion of dITP de-
rived from de novo pathways. Our findings suggest that previously 
reported variabiliry in sensitivity of epidermal cell!> in vitro to MTX 
{33] may be due in part to the presence and utilization of ex tracell u-
lar thymidine. 
In contrast to our demonstration that exogenous thymidine re-
verses the action of MTX, dipyridamole potentiates the cytotoxic 
action of MTX in human keratinocytes in vitro. This interaction 
with dipyridamole is not limited to MTX. Dipyridamole also po-
tentiated the growth-inhibitory activity of pirirrexim. a !leW lipo-
philic antifolarc with activity against psoriasis [34] (H. Reuveni , 
personal communication) and 5-FU, a pyrimidine antimetabolite, 
in human keratinocytes in vitro . l.n other experimental systems. this 
interaction between dipyridamole and inh.ibitOrs of pyrimidine: bio-
synthesis has been shown to be due to the simultaneous block of 
both salvage and de novo pathways to rhe formation of thymidine 
nudeotides [15 .20,21]. The ability of thymidine to reverse the ac-
tion of MTX and rhe ability of dipyridamole to potentiate rhe action 
of MTX substantiates this simultaneous blockade as the mechanism 
by which rhe combination ofMTX and dipyridamole acts synergis-
ticall y in keratinocytes. Moreover, it provides further evidence that 
human keratinocytes in vitro possess and utillu both !>alvage a.nd de: 
novo pathways for the biosynthesis of dTMP. The mechanism by 
which dipyridamole potentiates the action of 5-fluorouracil in ke-
tatinocyte:s was not explored. In other cell types this interaction has 
been attributed (Q the blockade of thymidylate synthase by FdUMP 
concurrently with either inhibition of the salvage of rhymidine or 
the intracellular accumulation of FdUMP because it is trapped in-
side the cell by the nuric-oside' transport inhibitor f18J. 
The systemic use of dipyridamole in combination with MTX. 
5-FU, or other agents is being tested in several maJignancies 122-
24]. The effective use of this combination therapy for wide-spread 
diseases such as cancer may be limited by a concommitant increase- in 
toxicity co normal cells. Moreover, extensive binding of dipyrida-
mole to plasma proteins after systemic adminisrration of the drug 
may make it impossible to achieve a plasma concentration of dipy-
ridamole that will be sufficienr [0 block thymidine ~a l vage in tissues 
[35J. Combinations of agents such as dipyridamole and methotrex-
ace or dipyridamole: a.nd 5-fluorouracil could be morc effective and 
less toxic when it is possib le to apply at least one of these agents 
topica.lIy. Several dermatologic diseases may be responsive to such a 
combination chemotherapeutic approach. 
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